-
Citi 11th Annual
Biotech Conference onSeptember 7, 2016 . Panel discussion at1:00 p.m. ET at theMandarin Oriental Hotel inBoston . -
Wells Fargo Securities Healthcare Conference , onSeptember 8, 2016 ,9:20 a.m. ET at theWestin Waterfront inBoston . -
Morgan Stanley Global Healthcare Conference onSeptember 13, 2016 ,4:05 p.m. ET at theGrand Hyatt inNew York . -
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on
September 29, 2016 at2:00 p.m. ET at the Lotte New York Palace inNew York .
To access the live webcast of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts; Seattle,
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, the risk that our
collaboration with
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005186/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Investors:
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Media:
Elizabeth
Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Pure
Communications, Inc.
Dan Budwick, 973-271-6085